DK4045039T3 - Hæmning af human integrin-alfa4beta7 - Google Patents
Hæmning af human integrin-alfa4beta7Info
- Publication number
- DK4045039T3 DK4045039T3 DK20875989.4T DK20875989T DK4045039T3 DK 4045039 T3 DK4045039 T3 DK 4045039T3 DK 20875989 T DK20875989 T DK 20875989T DK 4045039 T3 DK4045039 T3 DK 4045039T3
- Authority
- DK
- Denmark
- Prior art keywords
- alfa4beta7
- inhibition
- human integrin
- integrin
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Radio Relay Systems (AREA)
- Air Conditioning Control Device (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 | |
| PCT/US2020/055986 WO2021076890A1 (en) | 2019-10-16 | 2020-10-16 | INHIBITING HUMAN INTEGRIN α4β7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4045039T3 true DK4045039T3 (da) | 2025-06-30 |
Family
ID=73198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20875989.4T DK4045039T3 (da) | 2019-10-16 | 2020-10-16 | Hæmning af human integrin-alfa4beta7 |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20240174632A1 (da) |
| EP (3) | EP4045039B1 (da) |
| JP (7) | JP7437495B2 (da) |
| KR (2) | KR20220102669A (da) |
| CN (3) | CN115087444B (da) |
| AR (1) | AR120244A1 (da) |
| AU (2) | AU2020366435A1 (da) |
| BR (1) | BR112022007284A2 (da) |
| CA (1) | CA3154269A1 (da) |
| CL (1) | CL2022000959A1 (da) |
| CO (1) | CO2022005759A2 (da) |
| CR (1) | CR20220205A (da) |
| CU (1) | CU20220027A7 (da) |
| DK (1) | DK4045039T3 (da) |
| DO (2) | DOP2022000081A (da) |
| EC (1) | ECSP22038978A (da) |
| ES (1) | ES3035561T3 (da) |
| FI (1) | FI4045039T3 (da) |
| HR (1) | HRP20250749T1 (da) |
| HU (1) | HUE071814T2 (da) |
| IL (2) | IL319053A (da) |
| LT (1) | LT4045039T (da) |
| MA (1) | MA57399B1 (da) |
| MD (1) | MD4045039T2 (da) |
| MX (1) | MX2022004406A (da) |
| PE (1) | PE20221829A1 (da) |
| PH (1) | PH12022550886A1 (da) |
| PL (1) | PL4045039T3 (da) |
| PT (1) | PT4045039T (da) |
| RS (1) | RS66976B1 (da) |
| SI (1) | SI4045039T1 (da) |
| TW (6) | TWI857592B (da) |
| UA (1) | UA130059C2 (da) |
| UY (1) | UY38926A (da) |
| WO (3) | WO2021076902A1 (da) |
| ZA (2) | ZA202203872B (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| PE20221445A1 (es) | 2019-10-16 | 2022-09-21 | Chemocentryx Inc | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
| TWI857592B (zh) | 2019-10-16 | 2024-10-01 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素α4β7 |
| US20250195485A1 (en) * | 2021-12-27 | 2025-06-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and medical use thereof |
| EP4585587A1 (en) | 2022-09-09 | 2025-07-16 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and use thereof in medicine |
| EP4638438A1 (en) | 2022-12-22 | 2025-10-29 | Xinthera, Inc. | Alpha4 beta7 integrin antagonists and uses thereof |
| KR20250152075A (ko) * | 2023-02-21 | 2025-10-22 | 씨4엑스 디스커버리 리미티드 | 거대환식 알파4베타7 인테그린 억제제 |
| AU2024279767A1 (en) | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| CN119504796A (zh) * | 2024-11-20 | 2025-02-25 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195117T1 (de) | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| CA2268270A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Heterocyclic derivatives as factor xa inhibitors |
| EP0932615A1 (en) | 1996-10-11 | 1999-08-04 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1091945A1 (en) | 1998-06-29 | 2001-04-18 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| BR0010349B1 (pt) * | 1999-05-07 | 2011-10-04 | derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores. | |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| EP1214292B1 (en) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| CA2419699A1 (en) * | 2000-08-30 | 2002-03-07 | Pharmacia Corporation | Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| SI1485127T1 (sl) | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| HRP20120171T1 (hr) | 2004-09-03 | 2012-03-31 | Genentech | Humanizirani anti-beta 7 antagonisti i njihove uporabe |
| US7972775B2 (en) | 2005-03-03 | 2011-07-05 | Seedlings Life Science Ventures, Llc | Method of risk management for patients undergoing Natalizumab treatment |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| CA2610800A1 (en) | 2005-06-09 | 2006-12-14 | Ucb Pharma, S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
| ES2752137T3 (es) | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| WO2010091411A1 (en) | 2009-02-09 | 2010-08-12 | Glaxosmithkline Llc | Piperidinyl cyclic amido antiviral agents |
| AU2012236304C1 (en) | 2011-03-31 | 2017-01-05 | Genentech, Inc. | Methods of administering beta7 integrin antagonists |
| MX372664B (es) | 2012-10-05 | 2020-05-06 | Genentech Inc | Un antagonista de integrina beta7 para usarse en diagnosticar y tratar la enfermedad inflamatoria intestinal. |
| SG11201607938UA (en) | 2014-03-27 | 2016-10-28 | Genentech Inc | Methods for diagnosing and treating inflammatory bowel disease |
| WO2016011940A1 (zh) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| EP3262072A1 (en) | 2015-02-26 | 2018-01-03 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| TW201835078A (zh) * | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| JP7189368B2 (ja) * | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| TWI857592B (zh) | 2019-10-16 | 2024-10-01 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素α4β7 |
-
2020
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 EP EP25157767.2A patent/EP4559525A3/en active Pending
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko active Pending
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
- 2020-10-16 AU AU2020366435A patent/AU2020366435A1/en active Pending
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
- 2021-10-15 CN CN202180083775.8A patent/CN116783161A/zh active Pending
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP2024116230A/ja active Pending
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4045039T3 (da) | Hæmning af human integrin-alfa4beta7 | |
| DK3810581T3 (da) | Krystalmodifikationer af odevixibat | |
| DK3749181T3 (da) | Detektering af vævsbeskadigelse | |
| IL277778B (en) | Bcl6 inhibitors | |
| IL286218A (en) | Solid state forms of ripretinib | |
| DK4331584T3 (da) | Terapeutiske anvendelser af deutererede derivater af lanifibranor | |
| DK3773558T3 (da) | Kombinationsbehandling af artritisk sygdom | |
| DK3607068T3 (da) | RNA-interferensmedieret inhibering af TMPRSS6 | |
| DK3807260T3 (da) | Oprensning af nikotin | |
| DK3927899T3 (da) | Nedvibrering af funderinger | |
| DK3678644T3 (da) | Formuleringer af copanlisib | |
| DK3743064T3 (da) | Behandling af proteinuri | |
| IL285765A (en) | Therapeutic uses of dulaglutide | |
| DK3833378T3 (da) | Behandling af vorter | |
| DK3532072T3 (da) | Behandling af glaukom | |
| DK3746279T3 (da) | Sammenkobling af formdele | |
| DK3638370T3 (da) | Behandling af migræne med acetyl-leucin | |
| EP3962486A4 (en) | ESCAPEMENT OF USP36 | |
| IL285119A (en) | Use of spiropidion | |
| IL281409A (en) | Musk inhibition | |
| EP3996650C0 (en) | BATHTUB | |
| DK3781172T3 (da) | Behandling af lungebetændelse | |
| EP3936017A4 (en) | Bathtub | |
| DK3582764T3 (da) | Behandling af alkoholisme | |
| DK3720442T3 (da) | Inhibering af mutant idh-1 |